GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » Debt-to-EBITDA

Sinocelltech Group (SHSE:688520) Debt-to-EBITDA : -4.72 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sinocelltech Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ¥1,654 Mil. Sinocelltech Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ¥1,093 Mil. Sinocelltech Group's annualized EBITDA for the quarter that ended in Dec. 2023 was ¥-582 Mil. Sinocelltech Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -4.72.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sinocelltech Group's Debt-to-EBITDA or its related term are showing as below:

SHSE:688520' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.11   Med: -1.01   Max: 15.12
Current: -9.63

During the past 8 years, the highest Debt-to-EBITDA Ratio of Sinocelltech Group was 15.12. The lowest was -16.11. And the median was -1.01.

SHSE:688520's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs SHSE:688520: -9.63

Sinocelltech Group Debt-to-EBITDA Historical Data

The historical data trend for Sinocelltech Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinocelltech Group Debt-to-EBITDA Chart

Sinocelltech Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.45 -0.92 -1.38 -4.48 -16.11

Sinocelltech Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.54 -3.85 15.50 -12.98 -4.72

Competitive Comparison of Sinocelltech Group's Debt-to-EBITDA

For the Biotechnology subindustry, Sinocelltech Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinocelltech Group's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinocelltech Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sinocelltech Group's Debt-to-EBITDA falls into.



Sinocelltech Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sinocelltech Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1653.528 + 1092.52) / -170.446
=-16.11

Sinocelltech Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1653.528 + 1092.52) / -582.08
=-4.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Sinocelltech Group  (SHSE:688520) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sinocelltech Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sinocelltech Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinocelltech Group (SHSE:688520) Business Description

Traded in Other Exchanges
N/A
Address
Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.

Sinocelltech Group (SHSE:688520) Headlines

No Headlines